Vor Ort
Merkzettel Warenkorb
Produktbild: Neurotherapeutics in the Era of Translational Medicine

Neurotherapeutics in the Era of Translational Medicine

168,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

04.12.2020

Herausgeber

Richard A. Smith + weitere

Verlag

Elsevier Science & Technology

Seitenzahl

518

Maße (L/B/H)

23,4/19/2,2 cm

Gewicht

771 g

Sprache

Englisch

ISBN

978-0-12-816475-4

Beschreibung

Rezension

"Overall, this is a wonderful book for those interested in or familiar with neuroscience, neurological disease, and biotechnology, who wish to have a historical context while learning about the development of novel neurotherapeutic agents. There are few books that cover such a breadth and depth as this one does. It is quite helpful for its intended audience and does the subject justice. It is a worthy addition to any clinician-scientist's library." --© Doody Review, 2020, Ali A Saherwala, MD, reviewer, expert opinion

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

04.12.2020

Herausgeber

Verlag

Elsevier Science & Technology

Seitenzahl

518

Maße (L/B/H)

23,4/19/2,2 cm

Gewicht

771 g

Sprache

Englisch

ISBN

978-0-12-816475-4

EU-Ansprechpartner

Kolibri 360 GmbH
Ettore-Bugatti-Straße 6-14
51149 Köln
DE
produktsicherheit@kolibri360.de

Herstelleradresse

Elsevier Science & Technology
125 London Wall
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Neurotherapeutics in the Era of Translational Medicine

  • 1. Development of a molecular therapy for the SOD1 familial variant of ALS
    2. Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy
    3. Translating molecular therapies for spinal muscular atrophy
    4. From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy
    5. A novel treatment for Parkinson's disease and ALS: Combined cell
    and gene therapies
    6. Parkinson's disease: Genetic-driven therapeutic approaches
    7. Neural stem cell-mediated brain tumor therapy
    8. Advances in migraine therapeutics: The role of calcitonin
    gene-related peptide
    9. The impact of translational research on the development of therapeutic
    agents for multiple sclerosis
    10. Advances in treating myasthenia gravis 
    11. The endocannabinoid system as a target for the treatment
    of neurological disorders
    12. Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders
    13. 3D Alzheimer's disease in a dish: Implications for drug discovery
    14. Improving clinical trial efficiency with machine learning models
    of disease progression
    15. Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development 
    16. Repurposing FDA-approved pharmaceuticals: The development
    of Nuedexta
    17. Bioethics in the era of translational medicine
    18. Government efforts to promote the development of neurotherapeutics for the treatment of neurological diseases
    19. Innovative funding models for neurotherapeutics